Home › Funds › a16z Capital Management, L.L.C. › AKTS

a16z Capital Management, L.L.C. position in AKTS

AKTIS ONCOLOGY INC · Health Care

a16z Capital Management, L.L.C. reported holding 415,000 shares of AKTS (AKTIS ONCOLOGY INC) in its Q2 2026 13F filing — a position valued at US$13.4M, representing 0.09% of its reported portfolio and ranking #14 among its reported holdings. a16z Capital Management, L.L.C. has disclosed AKTS holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

Latest position (Q2 2026)415.00K sh
Reported value held$13.38M
Portfolio Weight0.09%
First reportedQ1 2026
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How a16z Capital Management, L.L.C.'s AKTS position evolved

a16z Capital Management, L.L.C. first disclosed a stake in AKTS in Q1 2026 at 415,000 shares (US$7.4M). The position peaked in Q2 2026 at 415,000 shares, worth US$13.4M. Across 2 filings, a16z Capital Management, L.L.C. held the position steady without any share-count change. The most recent filing (Q2 2026) shows 415,000 shares valued at US$13.4M.

Quarter by quarter

QuarterSharesValueChange
Q1 2026 415.00K $7.42M New
Q2 2026 415.00K $13.38M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About AKTS and 13F data

AKTS (AKTIS ONCOLOGY INC) is a Health Care company. 121 other funds we track also report a position in AKTS — the largest reported positions include MPM BioImpact LLC (US$155.9M), EcoR1 Capital, LLC (US$155.5M), Blue Owl Capital Holdings LP (US$99.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding AKTS

All AKTS fund holders →

FAQ

How long has a16z Capital Management, L.L.C. held AKTS?

a16z Capital Management, L.L.C. has disclosed AKTS holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

What is a16z Capital Management, L.L.C.'s current position in AKTS?

As of Q2 2026, a16z Capital Management, L.L.C. holds 415.00K shares of AKTS (AKTIS ONCOLOGY INC), valued at $13.38M, representing 0.09% of its reported portfolio and ranking #14.

Has a16z Capital Management, L.L.C. been buying or selling AKTS?

In the latest 13F filing (Q2 2026), a16z Capital Management, L.L.C. held unchanged its position in AKTS. The position peaked in Q2 2026 at 415.00K shares.

Which other funds hold AKTS?

Other major institutional holders of AKTS include MPM BioImpact LLC, EcoR1 Capital, LLC, Blue Owl Capital Holdings LP, among 121 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.